A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

Trial Profile

A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory CLL

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Inebilizumab (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 01 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 12 Nov 2015 Planned End Date changed from 1 Mar 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 12 Nov 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top